Join

Compare · ARGX vs INAB

ARGX vs INAB

Side-by-side comparison of argenx SE (ARGX) and IN8bio Inc. (INAB): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ARGX and INAB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • ARGX is the larger of the two at $54.76B, about 3862.2x INAB ($14.2M).
  • Over the past year, ARGX is up 51.2% and INAB is down 53.2% - ARGX leads by 104.4 points.
  • INAB has been more active in the news (8 items in the past 4 weeks vs 5 for ARGX).
  • ARGX has more recent analyst coverage (25 ratings vs 5 for INAB).
PerformanceARGX+51.24%INAB-53.17%
2025-06-09+0.00%2026-06-08
MetricARGXINAB
Company
argenx SE
IN8bio Inc.
Price
$882.63-1.03%
$1.44-2.04%
Market cap
$54.76B
$14.2M
1M return
+12.11%
-9.15%
1Y return
+51.24%
-53.17%
Sector
Health Care
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2017
2021
News (4w)
5
8
Recent ratings
25
5
ARGX

argenx SE

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

INAB

IN8bio Inc.

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Latest ARGX

Latest INAB